These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30589457)

  • 1. Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors.
    Crass RL; Pai MP
    Pharmacotherapy; 2019 Feb; 39(2):182-195. PubMed ID: 30589457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What are the optimal pharmacokinetic/pharmacodynamic targets for β-lactamase inhibitors? A systematic review.
    Assefa GM; Roberts JA; Mohammed SA; Sime FB
    J Antimicrob Chemother; 2024 May; 79(5):946-958. PubMed ID: 38459763
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
    Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
    Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations.
    Sy SKB; Derendorf H
    Clin Microbiol Infect; 2018 Jul; 24(7):707-715. PubMed ID: 28760708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-lactam/β-lactamase inhibitor combinations: from then to now.
    Toussaint KA; Gallagher JC
    Ann Pharmacother; 2015 Jan; 49(1):86-98. PubMed ID: 25361682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics-Pharmacodynamics of CB-618 in Combination with Cefepime, Ceftazidime, Ceftolozane, or Meropenem: the Pharmacological Basis for a Stand-Alone β-Lactamase Inhibitor.
    Ambrose PG; VanScoy BD; Trang M; McCauley-Miller J; Conde H; Bhavnani SM; Alexander DC; Friedrich LV
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination beta-lactam and beta-lactamase-inhibitor products: antimicrobial activity and efficiency of enzyme inhibition.
    Rotschafer JC; Ostergaard BE
    Am J Health Syst Pharm; 1995 Mar; 52(6 Suppl 2):S15-22. PubMed ID: 7606585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
    Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avibactam Pharmacokinetic/Pharmacodynamic Targets.
    Nichols WW; Newell P; Critchley IA; Riccobene T; Das S
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of 13 beta-lactam agents combined with BRL 42715 against beta-lactamase producing gram-negative bacteria compared to combinations with clavulanic acid, tazobactam and sulbactam.
    Piddock LJ; Jin YF; Turner HL
    J Antimicrob Chemother; 1993 Jan; 31(1):89-103. PubMed ID: 8383105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of novel β-lactams and β-lactam/β-lactamase inhibitor combinations with implications for pediatric use.
    Olney KB; Thomas JK; Johnson WM
    Pharmacotherapy; 2023 Jul; 43(7):713-731. PubMed ID: 36825478
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
    mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.
    Vanjak D; Muller-Serieys C; Picard B; Bergogne-Berezin E; Lambert-Zechovsky N
    Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):972-8. PubMed ID: 8654448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".
    Papp-Wallace KM; Mack AR; Taracila MA; Bonomo RA
    Infect Dis Clin North Am; 2020 Dec; 34(4):773-819. PubMed ID: 33011051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing pharmacokinetics/pharmacodynamics of β-lactam/β-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria.
    Tam VH; Abodakpi H; Wang W; Ledesma KR; Merlau PR; Chan K; Altman R; Tran TT; Nikolaou M; Sofjan AK
    J Antimicrob Chemother; 2021 Jan; 76(1):179-183. PubMed ID: 33035321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.